Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8666950 | 0.89 | DPP4 (0.41) | OPRM1SLC6A3SLC6A4 | |
| SCHEMBL7003423 | 0.87 | SLC6A2 (0.41) | OPRM1SLC6A3SLC6A4 | |
| SCHEMBL21574981 | 0.85 | ACHE (0.43) | HDAC6SLC6A3HSD11B1RORCSLC6A4 | |
| SCHEMBL1569110 | 0.83 | DPP4 (0.38) | OPRM1 | |
| SCHEMBL1256629 | 0.83 | ESR2 (0.46) | — | |
| SCHEMBL12893261 | 0.81 | ESR2 (0.47) | — | |
| SCHEMBL21574987 | 0.80 | HDAC6 (0.41) | HDAC6SLC6A3HSD11B1SLC6A4 | |
| SCHEMBL21574977 | 0.79 | ACHE (0.45) | HDAC6SLC6A3RORCSLC6A4 | |
| SCHEMBL21575094 | 0.79 | HDAC6 (0.44) | HDAC6SLC6A3HSD11B1SLC6A4 | |
| SCHEMBL21575093 | 0.79 | HDAC6 (0.47) | HDAC6OPRM1SLC6A3HSD11B1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745389-B2 | HDAC6 selective inhibitors, preparation method therefor, and application thereof | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745389-B2 | HDAC6 selective inhibitors, preparation method therefor, and application thereof | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885OPRM1 4703/4885SLC6A3 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.